Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow.

Source: NYT Health - July 16, 2016 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Drugs (Pharmaceuticals) Biotechnology and Bioengineering Generic Brands and Products Prices (Fares, Fees and Rates) Amgen Inc AbbVie Inc Source Type: news